PT3609529T - Arn para tratamento de doenças autoimunes - Google Patents

Arn para tratamento de doenças autoimunes

Info

Publication number
PT3609529T
PT3609529T PT187175807T PT18717580T PT3609529T PT 3609529 T PT3609529 T PT 3609529T PT 187175807 T PT187175807 T PT 187175807T PT 18717580 T PT18717580 T PT 18717580T PT 3609529 T PT3609529 T PT 3609529T
Authority
PT
Portugal
Prior art keywords
rna
treatment
autoimmune diseases
autoimmune
diseases
Prior art date
Application number
PT187175807T
Other languages
English (en)
Original Assignee
Tron Translationale Onkologie An Der Univ Der Johannes Gutenberg Univ Mainz Gemeinnuetzige Gmbh
BioNTech SE
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tron Translationale Onkologie An Der Univ Der Johannes Gutenberg Univ Mainz Gemeinnuetzige Gmbh, BioNTech SE filed Critical Tron Translationale Onkologie An Der Univ Der Johannes Gutenberg Univ Mainz Gemeinnuetzige Gmbh
Publication of PT3609529T publication Critical patent/PT3609529T/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
    • A61K48/0033—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid the non-active part being non-polymeric
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1003—Extracting or separating nucleic acids from biological samples, e.g. pure separation or isolation methods; Conditions, buffers or apparatuses therefor
    • C12N15/1006—Extracting or separating nucleic acids from biological samples, e.g. pure separation or isolation methods; Conditions, buffers or apparatuses therefor by means of a solid support carrier, e.g. particles, polymers
    • C12N15/101—Extracting or separating nucleic acids from biological samples, e.g. pure separation or isolation methods; Conditions, buffers or apparatuses therefor by means of a solid support carrier, e.g. particles, polymers by chromatography, e.g. electrophoresis, ion-exchange, reverse phase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/117—Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6018—Lipids, e.g. in lipopeptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base
    • C12N2310/335—Modified T or U

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Mycology (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Analytical Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
PT187175807T 2017-04-11 2018-04-10 Arn para tratamento de doenças autoimunes PT3609529T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/EP2017/058651 WO2018188730A1 (en) 2017-04-11 2017-04-11 Rna for treatment of autoimmune diseases

Publications (1)

Publication Number Publication Date
PT3609529T true PT3609529T (pt) 2021-10-14

Family

ID=58632945

Family Applications (1)

Application Number Title Priority Date Filing Date
PT187175807T PT3609529T (pt) 2017-04-11 2018-04-10 Arn para tratamento de doenças autoimunes

Country Status (22)

Country Link
US (2) US11701413B2 (pt)
EP (2) EP3981424A1 (pt)
JP (3) JP7078641B2 (pt)
KR (2) KR20190134765A (pt)
CN (2) CN118161602A (pt)
AU (1) AU2018253352A1 (pt)
BR (1) BR112019020667A8 (pt)
CA (1) CA3059505A1 (pt)
CY (1) CY1124767T1 (pt)
DK (1) DK3609529T3 (pt)
ES (1) ES2893451T3 (pt)
HR (1) HRP20211559T1 (pt)
HU (1) HUE056871T2 (pt)
IL (2) IL269793B (pt)
LT (1) LT3609529T (pt)
MX (1) MX2019012144A (pt)
PL (1) PL3609529T3 (pt)
PT (1) PT3609529T (pt)
RS (1) RS62582B1 (pt)
SG (2) SG11201909520VA (pt)
SI (1) SI3609529T1 (pt)
WO (2) WO2018188730A1 (pt)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020102172A2 (en) * 2018-11-12 2020-05-22 Translate Bio, Inc. Methods for inducing immune tolerance
GB2594364A (en) * 2020-04-22 2021-10-27 Biontech Rna Pharmaceuticals Gmbh Coronavirus vaccine
US11058751B1 (en) 2020-11-20 2021-07-13 Think Therapeutics, Inc. Compositions for optimized RAS peptide vaccines
US11421015B2 (en) 2020-12-07 2022-08-23 Think Therapeutics, Inc. Method of compact peptide vaccines using residue optimization
US11161892B1 (en) 2020-12-07 2021-11-02 Think Therapeutics, Inc. Method of compact peptide vaccines using residue optimization
CN115232825B (zh) * 2021-04-22 2023-09-26 中国人民解放军军事科学院军事医学研究院 一种基于1083骨架的新冠病毒疫苗
US11464842B1 (en) 2021-04-28 2022-10-11 Think Therapeutics, Inc. Compositions and method for optimized peptide vaccines using residue optimization
CN117750971A (zh) 2021-05-26 2024-03-22 易姆赛斯股份公司 治疗或预防自身免疫病的方法
AR126654A1 (es) 2021-06-29 2023-11-01 Imcyse Sa Péptidos y métodos para el tratamiento de neuromielitis óptica
CN113336862B (zh) * 2021-07-05 2022-03-01 广东省科学院动物研究所 一种抗多发性硬化的重组蛋白及其制备方法和用途
WO2023030635A1 (en) * 2021-09-02 2023-03-09 BioNTech SE Potency assay for therapeutic potential of coding nucleic acid
WO2023131254A1 (zh) * 2022-01-06 2023-07-13 上海吉量医药工程有限公司 N1位修饰假尿嘧啶核苷及其在mRNA合成中的应用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7030098B2 (en) * 1999-03-12 2006-04-18 The Board Of Trustees Of The Leland Stanford Junior University DNA vaccination for treatment of autoimmune disease
AU2002952834A0 (en) * 2002-09-16 2002-12-05 The Walter And Eliza Hall Institute Of Medical Research A method of treating an autoimmune disease
US9012219B2 (en) 2005-08-23 2015-04-21 The Trustees Of The University Of Pennsylvania RNA preparations comprising purified modified RNA for reprogramming cells
SI3611266T1 (sl) * 2005-08-23 2023-02-28 The Trustees Of The University Of Pennsylvania Modificirani nukleozidi, ki vsebujejo RNA, in postopki za njihovo uporabo
WO2009030254A1 (en) * 2007-09-04 2009-03-12 Curevac Gmbh Complexes of rna and cationic peptides for transfection and for immunostimulation
EP2050814A1 (en) 2007-10-17 2009-04-22 Txcell Compositions for treating multiple sclerosis
US8808982B2 (en) * 2009-12-07 2014-08-19 Cellscript, Llc Compositions and methods for reprogramming eukaryotic cells
WO2012154933A1 (en) * 2011-05-10 2012-11-15 The Brigham And Women's Hospital, Inc. Detecting inclusion body myositis
WO2013044419A1 (en) * 2011-09-30 2013-04-04 Beijing Advaccine Biotechnology Co., Ltd. Combined facilitator, antigen and dna vaccine for preventing and treating autoimmune diseases
CA2862377A1 (en) * 2011-12-30 2013-07-04 Cellscript, Llc Making and using in vitro-synthesized ssrna for introducing into mammalian cells to induce a biological or biochemical effect
WO2013120498A1 (en) * 2012-02-15 2013-08-22 Curevac Gmbh Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded allergenic antigen or an autoimmune self-antigen
WO2014160243A1 (en) * 2013-03-14 2014-10-02 The Trustees Of The University Of Pennsylvania Purification and purity assessment of rna molecules synthesized with modified nucleosides
EP3289083A4 (en) * 2015-04-27 2018-12-19 The Trustees Of The University Of Pennsylvania Nucleoside-modified rna for inducing an adaptive immune response
CN106395552B (zh) * 2015-08-03 2020-03-17 奥的斯电梯公司 无绳电梯系统导轨组件
EP4029522A1 (en) * 2015-08-28 2022-07-20 BioNTech SE Method for reducing immunogenicity of rna
EP4008782A1 (en) 2016-04-22 2022-06-08 BioNTech SE Methods for providing single-stranded rna

Also Published As

Publication number Publication date
HUE056871T2 (hu) 2022-04-28
JP2020516658A (ja) 2020-06-11
RU2019135808A3 (pt) 2021-08-10
WO2018188730A1 (en) 2018-10-18
JP2022110127A (ja) 2022-07-28
CA3059505A1 (en) 2018-10-18
KR20240042138A (ko) 2024-04-01
CN118161602A (zh) 2024-06-11
EP3609529A1 (en) 2020-02-19
BR112019020667A8 (pt) 2022-08-16
US11701413B2 (en) 2023-07-18
CN110719787B (zh) 2024-03-15
IL290980A (en) 2022-05-01
AU2018253352A1 (en) 2019-10-17
MX2019012144A (es) 2019-11-21
SG11201909520VA (en) 2019-11-28
CY1124767T1 (el) 2022-11-25
JP7078641B2 (ja) 2022-05-31
EP3981424A1 (en) 2022-04-13
LT3609529T (lt) 2021-10-25
RS62582B1 (sr) 2021-12-31
CN110719787A (zh) 2020-01-21
JP7444924B2 (ja) 2024-03-06
BR112019020667A2 (pt) 2020-05-05
ES2893451T3 (es) 2022-02-09
US20200061166A1 (en) 2020-02-27
PL3609529T3 (pl) 2021-12-13
IL269793A (en) 2019-11-28
SI3609529T1 (sl) 2021-11-30
EP3609529B1 (en) 2021-09-08
WO2018189193A1 (en) 2018-10-18
JP2024059794A (ja) 2024-05-01
RU2019135808A (ru) 2021-05-11
SG10202111163VA (en) 2021-11-29
IL269793B (en) 2022-04-01
KR20190134765A (ko) 2019-12-04
DK3609529T3 (da) 2021-10-11
US20230330198A1 (en) 2023-10-19
HRP20211559T1 (hr) 2022-01-21

Similar Documents

Publication Publication Date Title
IL290980A (en) Rna for the treatment of autoimmune diseases
HK1256795A1 (zh) 可用於治療自身免疫疾病的二吡唑基衍生物
IL261935A (en) Methods for treating gallstone disease
ZA201903003B (en) Treatment of neurological diseases
HK1258994A1 (zh) 用於疾病治療的方法
GB201516905D0 (en) Treatment of Neurodegenerative diseases
EP3716949A4 (en) METHODS OF TREATING AN AUTOIMMUNE DISEASE
GB201412578D0 (en) Treatment of neurological diseases
GB201714307D0 (en) Treatment of neurodegenerative diseases
GB201805100D0 (en) Treatment of sarcopenic diseases
HK1243937A1 (zh) 治療疾病的方法
EP3376869A4 (en) AUTOIMMUNE DISEASE TREATMENT
GB201714303D0 (en) Treatment of neurodegenerative diseases
GB201714311D0 (en) Treatment of neurodegenerative diseases
IL259953A (en) Liposomes for treatment of an autoimmune disease
GB201514909D0 (en) Treatment of autoimmune diseases
GB201604253D0 (en) Treatment of genetic diseases
GB201517565D0 (en) Treatment of genetic diseases
GB201706662D0 (en) Treatment of neurological diseases
GB201704666D0 (en) Treatment of neurodegenerative diseases
GB201621398D0 (en) Treatment of emt-associated disease
GB201414023D0 (en) Treatment of autoimmune diseases
GB201504413D0 (en) Treatment of disease